Bristol Myers Squibb’s subcutaneous nivolumab shows promise in Phase 3 RCC trial
Bristol Myers Squibb (NYSE: BMY) has announced results from its Phase 3 CheckMate -67T trial, which could revolutionize treatment for patients with advanced or metastatic ... Read More
Merck’s KEYTRUDA shows 38% reduction in death risk for renal cell carcinoma patients in Phase 3 KEYNOTE-564 trial
Merck & Co., Inc., a global healthcare leader, has recently unveiled groundbreaking results from its Phase 3 KEYNOTE-564 trial. This pivotal study demonstrates that KEYTRUDA, ... Read More
Merck’s WELIREG meets primary endpoint of PFS in Phase 3 RCC trial
Global pharmaceutical leader Merck has announced that WELIREG (belzutifan), its pioneering oral HIF-2α inhibitor, has achieved a critical milestone in its Phase 3 trial LITESPARK-005. ... Read More
LG Chem to acquire US biotech company Aveo Oncology for $566m
LG Chem acquisition of Aveo Oncology : South Korea’s LG Chem has entered into a definitive agreement to acquire Aveo Oncology, a US-based biotech company, ... Read More
FDA approves Opdivo and Cabometyx combo for advanced kidney cancer treatment
The U.S. Food and Drug Administration (FDA) has officially approved the combination of Bristol Myers Squibb's Opdivo (nivolumab) and Exelixis' Cabometyx (cabozantinib) for the first-line ... Read More
Merck to acquire US biopharma company Peloton Therapeutics in $2.2bn deal
Merck acquisition of Peloton : Pharma giant Merck is set to acquire US biopharma company Peloton Therapeutics in a deal worth up to $2.2 billion, ... Read More